Antiretroviral boosting by cobicistat, a structural analog of ritonavir

Clinical Pharmacology in Drug Development

Volumn 3, Issue 5, 2014, Pages 335-337

  Greenblatt, David J ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COBICISTAT; COBICISTAT PLUS ELVITEGRAVIR PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; CYCLOSPORIN; CYTOCHROME P450 3A; KETOCONAZOLE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MULTIDRUG RESISTANCE PROTEIN; RITONAVIR;

DRUG APPROVAL; DRUG CLEARANCE; DRUG COST; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; EDITORIAL; ENZYME INHIBITION; HUMAN; LOW DRUG DOSE;

EID: 84908555770     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.159     Document Type: Editorial

References (25)

1. Greenblatt DJ, von Moltke LL. Clinical studies of drug-drug interactions: design and interpretation. In: Pang KS, Rodrigues AD, Peter RM eds. Enzyme and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges. New York: Springer; 2010: 625-649.
2. von Moltke LL, Greenblatt DJ. Clinical drug interactions due to metabolic inhibition: prediction, assessment, and interpretation. In: Lu C, Li AP eds. Enzyme Inhibition in Drug Discovery and Development. Hoboken, NJ: John Wiley & Sons; 2010: 533-547.
3. Keogh A, Spratt P, McCosker C, Macdonald P, Mundy J, Kaan A. Ketoconazole to reduce the need for cyclosporine after cardiac transplantation. N Engl J Med. 1995; 333:628-633.
4. Jones TE. The use of other drugs to allow a lower dosage of cyclosporin to be used. Clin Pharmacokinet. 1997; 32:357-367.
5. Abraham MA, Thomas PP, John GT, Job V, Shankar V, Jacob CK. Efficacy and safety of low-dose ketoconazole (50mg) to reduce the cost of cyclosporine in renal allograft recipients. Transplant Proc. 2003; 35:215-216.
6. Gerntholtz T, Pascoe MD, Botha JF, Halkett J, Kahn D. The use of a cyclosporin-ketoconazole combination: making renal transplantation affordable in developing countries. Eur J Clin Pharmacol. 2004; 60:143-148.
7. Flexner C. Dual protease inhibitor therapy in HIV-infected patients: pharmacologic rationale and clinical benefits. Annu Rev Pharmacol Toxicol. 2000; 40:649-674.
8. Hull MW, Montaner JS. Ritonavir-boosted protease inhibitors in HIV therapy. Ann Med. 2011; 43:375-388.
9. von Hentig N, Haberl A. Safety of pharmacoenhancers for HIV therapy. Exp Rev Clin Pharmacol. 2012; 5:557-568.
10. Sham HL, Kempf DJ, Molla A, et al. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother. 1998; 42:3218-3224.
11. Shah BM, Schafer JJ, Priano J, Squires KE. Cobicistat: a new boost for the treatment of human immunodeficiency virus infection. Pharmacotherapy. 2013; 33:1107-1116.
12. Capetti A, Rizzardini G. Cobicistat: a new opportunity in the treatment of HIV disease? Exp Opin Pharmacother. 2014; 15:1289-1298.
13. Perry CM. Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults. Drugs. 2014; 74:75-97.
14. Deeks ED. Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection. Drugs. 2014; 74:195-206.
15. von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol. 1998; 38:106-111.
16. von Moltke LL, Durol ALB, Duan SX, Greenblatt DJ. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur J Clin Pharmacol. 2000; 56:259-261.
17. Xu L, Liu H, Murray BP, et al. Cobicistat (GS-9350): a potent and selective inhibitor of human CYP3A as a novel pharmacoenhancer. ACS Med Chem Lett. 2010; 1:209-213.
18. Sevrioukova IF, Poulos TL. Dissecting cytochrome P450 3A4-ligand interactions using ritonavir analogues. Biochemistry. 2013; 52:4474-4481.
19. Sevrioukova IF, Poulos TL. Ritonavir analogues as a probe for deciphering the cytochrome P450 3A4 inhibitory mechanism. Curr Top Med Chem. 2014; 14:1348-1355.
20. Mathias AA, German P, Murray BP, et al. Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity. Clin Pharmacol Ther. 2010; 87:322-329.
21. Kakuda TN, Opsomer M, Timmers M, et al. Pharmacokinetics of darunavir in fixed-dose combination with cobicistat compared with coadministration of darunavir and ritonavir as single agents in healthy volunteers. J Clin Pharmacol. 2014; 54:949-957.
22. Elion R, Cohen C, Gathe J, et al. Phase 2 study of cobicistat versus ritonavir each with once-daily atazanavir and fixed-dose emtricitabine/tenofovir df in the initial treatment of HIV infection. AIDS. 2011; 25:1881-1886.
23. DeJesus E, Rockstroh JK, Henry K, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012; 379:2429-2438.
24. Gallant JE, Koenig E, Andrade-Villanueva J, et al. Cobicistat versus ritonavir as a pharmacoenhancer of atazanavir plus emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV type 1-infected patients: week 48 results. J Infect Dis. 2013; 208:32-39.
25. Greenblatt DJ. The ketoconazole legacy. Clin Pharmacol Drug Dev. 2014; 3:1-3.